NYBC Ventures

NYBC Ventures is a specialized investment fund established by New York Blood Center Enterprises (NYBCe) to advance innovations in blood-related fields and cellular therapies. With a $50 million commitment, the fund aims to improve patient outcomes by supporting therapeutics, devices, and technologies that address critical challenges in hematology, transfusion medicine, cell therapy, and infectious diseases. The fund's mission is to foster collaborations that expand NYBCe's impact in these areas.

The fund's investment strategy focuses on early and established companies developing breakthrough solutions in its target sectors. By leveraging NYBCe's extensive network and expertise, NYBC Ventures seeks to identify and support companies that are advancing life-saving therapies and technologies. The fund's approach combines financial investment with strategic guidance to accelerate the growth and impact of its portfolio companies.

Since its inception, NYBC Ventures has made multiple investments, including a recent seed round in Catena Biosciences. The fund continues to seek opportunities to invest in companies that align with its mission and strategic focus, aiming to drive significant advancements in blood and cell-based therapies and technologies.